There is research on this stock available only to PRO subscribers.
- VRS-317 offers a potentially best in class dosage schedule, which will translate into a competitive edge.
- Versartis has the potential to grab a significant market-share of the HGH market.
- Versartis is facing a pending catalyst with the release of its clinical data in June from its VERTICAL trial.
- Versartis recently completed its IPO and saw its shares rise on high demand after the offering.
- The Company is attempting to provide a longer lasting treatment to growth hormone deficiency.
- Prior attempts from other companies to provide a long-acting growth hormone have failed.
- The company's limited product pipeline concentrates investor risk.
- VSAR, an endocrine-focused biopharmaceutical firm in the process of developing a treatment for growth hormone deficiency, plans to raise $80.5 million in its upcoming IPO.
- VSAR will offer 4.6 million shares at an expected price range of $16-$19 per share.
- While VSAR could be sitting on a goldmine, it is a long way from commercializing VRS-317, and there's certainly no guarantee that VRS-317 will gain FDA approval.
- Endocrine-focused biopharmaceutical company.
- Lead product intended to reduce the burden of daily treatment by requiring significantly fewer injections, potentially improving compliance and, therefore, treatment outcomes.
- In phase 2b clinical trials.